{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:36:38Z","timestamp":1772138198166,"version":"3.50.1"},"reference-count":57,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2017,12,20]],"date-time":"2017-12-20T00:00:00Z","timestamp":1513728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/about_us\/legal\/notices"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,5,17]]},"DOI":"10.1093\/cid\/cix1106","type":"journal-article","created":{"date-parts":[[2017,12,16]],"date-time":"2017-12-16T23:06:49Z","timestamp":1513465609000},"page":"1742-1750","source":"Crossref","is-referenced-by-count":23,"title":["Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes"],"prefix":"10.1093","volume":"66","author":[{"given":"Zobair M","family":"Younossi","sequence":"first","affiliation":[{"name":"Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, Virginia"},{"name":"Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, Virginia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Stepanova","sequence":"additional","affiliation":[{"name":"Center for Outcomes Research in Liver Disease, Washington, D.C"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarik","family":"Asselah","sequence":"additional","affiliation":[{"name":"Centre de Recherche sur l\u2019Inflammation, Institut national de la sant\u00e9 et de la recherche m\u00e9dicale, Unit\u00e9 mixte de recherche, Universit\u00e9 Paris Diderot, Department of Hepatology, H\u00f4pital Beaujon, Assistance Publique\u2013H\u00f4pitaux de Paris, Clichy, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham","family":"Foster","sequence":"additional","affiliation":[{"name":"Queen Mary University of London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keyur","family":"Patel","sequence":"additional","affiliation":[{"name":"Toronto Center for Liver Disease, University of Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Br\u00e4u","sequence":"additional","affiliation":[{"name":"James J. Peters Veterans Affairs Medical Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Swain","sequence":"additional","affiliation":[{"name":"Calgary Liver Unit, Division of Gastroenterology and Hepatology, Cumming School of Medicine, University of Calgary, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tram","family":"Tran","sequence":"additional","affiliation":[{"name":"Liver Transplantation, Cedars-Sinai Medical Center, Los Angeles, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Esteban","sequence":"additional","affiliation":[{"name":"Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d\u2019Hebron and Universitat Aut\u00f2noma de Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Colombo","sequence":"additional","affiliation":[{"name":"Humanitas Clinical and Research Center, Humanitas Research Hospital, Rozzano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Pianko","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Monash Health, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Henry","sequence":"additional","affiliation":[{"name":"Center for Outcomes Research in Liver Disease, Washington, D.C"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Bourliere","sequence":"additional","affiliation":[{"name":"Hospital St Joseph, Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,12,20]]},"reference":[{"key":"key\n\t\t\t\t20180517005612_CIT0001","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrgastro.2013.107","article-title":"Epidemiology and natural history of HCV infection","volume":"10","author":"Hajarizadeh","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20180517005612_CIT0002","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jhep.2016.07.005","article-title":"Hepatitis C infection: a multi-faceted systemic disease with clinical, patient reported and economic consequences","volume":"65","author":"Younossi","year":"2016","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20180517005612_CIT0003","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/apt.13090","article-title":"Systematic review: patient-reported outcomes in chronic hepatitis C\u2014the impact of liver disease and new treatment regimens","volume":"41","author":"Younossi","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180517005612_CIT0004","doi-asserted-by":"crossref","first-page":"S186","DOI":"10.1016\/j.dld.2014.09.025","article-title":"The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C","volume":"46","author":"Younossi","year":"2014","journal-title":"Dig Liver Dis"},{"key":"key\n\t\t\t\t20180517005612_CIT0005","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1007\/s10620-006-9708-x","article-title":"Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection","volume":"52","author":"Kallman","year":"2007","journal-title":"Dig Dis Sci"},{"key":"key\n\t\t\t\t20180517005612_CIT0006","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1053\/j.gastro.2016.02.039","article-title":"Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden","volume":"150","author":"Younossi","year":"2016","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180517005612_CIT0007","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/hep.510270132","article-title":"Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis","volume":"27","author":"Foster","year":"1998","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20180517005612_CIT0008","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/hep.510300203","article-title":"Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group","volume":"30","author":"Ware","year":"1999","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20180517005612_CIT0009","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/hep.20014","article-title":"Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection","volume":"39","author":"Dalgard","year":"2004","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20180517005612_CIT0010","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/hep.510300504","article-title":"The impact of diagnosis of hepatitis C virus on quality of life","volume":"30","author":"Rodger","year":"1999","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20180517005612_CIT0011","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.cgh.2015.07.035","article-title":"Effects of viral eradication with ledipasvir and sofosbuvir, with or without ribavirin, on measures of fatigue in patients with chronic hepatitis C virus infection","volume":"14","author":"Gerber","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20180517005612_CIT0012","doi-asserted-by":"crossref","first-page":"8169","DOI":"10.1128\/JVI.00974-13","article-title":"Hepatitis C virus infection induces inflammatory cytokines and chemokines mediated by the cross talk between hepatocytes and stellate cells","volume":"87","author":"Nishitsuji","year":"2013","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180517005612_CIT0013","doi-asserted-by":"crossref","first-page":"528","DOI":"10.4254\/wjh.v5.i10.528","article-title":"Chronic HCV infection and inflammation: clinical impact on hepatic and extra-hepatic manifestations","volume":"5","author":"Zampino","year":"2013","journal-title":"World J Hepatol"},{"key":"key\n\t\t\t\t20180517005612_CIT0014","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/jvh.12448","article-title":"Ledipasvir\/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels","volume":"22","author":"Younossi","year":"2015","journal-title":"J Viral Hepat"},{"key":"key\n\t\t\t\t20180517005612_CIT0015","doi-asserted-by":"crossref","first-page":"e5066","DOI":"10.1097\/MD.0000000000005066","article-title":"The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV)","volume":"95","author":"Golabi","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"key\n\t\t\t\t20180517005612_CIT0016","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.cld.2017.03.008","article-title":"Neurologic manifestations of hepatitis C virus infection","volume":"21","author":"Iriana","year":"2017","journal-title":"Clin Liver Dis"},{"key":"key\n\t\t\t\t20180517005612_CIT0017","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.cld.2017.03.007","article-title":"Chronic hepatitis C virus infection and depression","volume":"21","author":"Adinolfi","year":"2017","journal-title":"Clin Liver Dis"},{"key":"key\n\t\t\t\t20180517005612_CIT0018","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.cld.2017.03.004","article-title":"Metabolic manifestations of hepatitis C virus: diabetes mellitus, dyslipidemia","volume":"21","author":"Serfaty","year":"2017","journal-title":"Clin Liver Dis"},{"key":"key\n\t\t\t\t20180517005612_CIT0019","doi-asserted-by":"crossref","first-page":"637","DOI":"10.7326\/M16-2575","article-title":"Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review","volume":"166","author":"Falade-Nwulia","year":"2017","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20180517005612_CIT0020","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.3748\/wjg.v22.i19.4615","article-title":"Current treatment of chronic hepatitis C in China: dilemma and potential problems","volume":"22","author":"Han","year":"2016","journal-title":"World J Gastroenterol"},{"key":"key\n\t\t\t\t20180517005612_CIT0021","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S2468-1253(16)30080-2","article-title":"Management of hepatitis C virus infection in the Asia-Pacific region: an update","volume":"2","author":"Lim","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20180517005612_CIT0022","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/jvh.12635","article-title":"Pan-genotypic treatment regimens for hepatitis C virus: advantages and disadvantages in high- and low-income regions","volume":"24","author":"H\u00e9zode","year":"2017","journal-title":"J Viral Hepat"},{"key":"key\n\t\t\t\t20180517005612_CIT0023","author":"World Health Organization"},{"key":"key\n\t\t\t\t20180517005612_CIT0024","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/ajg.2016.99","article-title":"An in-depth analysis of patient-reported outcomes in patients with chronic hepatitis C treated with different anti-viral regimens","volume":"111","author":"Younossi","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20180517005612_CIT0025","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/apt.13269","article-title":"The patient\u2019s journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens: a study of health-related quality of life","volume":"42","author":"Younossi","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180517005612_CIT0026","doi-asserted-by":"crossref","first-page":"e5048","DOI":"10.1097\/MD.0000000000005048","article-title":"Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: the quality-adjusted cost of care","volume":"95","author":"Younossi","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"key\n\t\t\t\t20180517005612_CIT0027","first-page":"16","article-title":"Sofosbuvir-based regimens with task shifting is cost-effective in expanding hepatitis C treatment access in the United States","volume":"5","author":"Jayasekera","year":"2017","journal-title":"J Clin Transl Hepatol"},{"key":"key\n\t\t\t\t20180517005612_CIT0028","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.cld.2017.03.012","article-title":"Economic burden of hepatitis C infection","volume":"21","author":"Stepanova","year":"2017","journal-title":"Clin Liver Dis"},{"key":"key\n\t\t\t\t20180517005612_CIT0029","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/jvh.12506","article-title":"Disparate access to treatment regimens in chronic hepatitis C patients: data from the TRIO network","volume":"23","author":"Younossi","year":"2016","journal-title":"J Viral Hepat"},{"key":"key\n\t\t\t\t20180517005612_CIT0030","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/apt.13081","article-title":"Cost-effectiveness of all-oral ledipasvir\/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection","volume":"41","author":"Younossi","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180517005612_CIT0031","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/jvh.12483","article-title":"Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries","volume":"23","author":"Younossi","year":"2016","journal-title":"J Viral Hepat"},{"key":"key\n\t\t\t\t20180517005612_CIT0032","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1002\/hep.27161","article-title":"Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens","volume":"59","author":"Younossi","year":"2014","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20180517005612_CIT0033","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jhep.2015.03.014","article-title":"Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir","volume":"63","author":"Younossi","year":"2015","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20180517005612_CIT0034","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S2468-1253(16)30009-7","article-title":"Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial","volume":"1","author":"Younossi","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20180517005612_CIT0035","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180517005612_CIT0036","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180517005612_CIT0037","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180517005612_CIT0038","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jama.2014.7734","article-title":"Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection","volume":"312","author":"Sulkowski","year":"2014","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180517005612_CIT0039","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180517005612_CIT0040","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180517005612_CIT0041","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180517005612_CIT0042","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180517005612_CIT0043","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180517005612_CIT0044","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180517005612_CIT0045","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection","volume":"376","author":"Bourli\u00e8re","year":"2017","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180517005612_CIT0046","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-Item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"key\n\t\t\t\t20180517005612_CIT0047","first-page":"604","article-title":"The functional assessment of chronic illness therapy (FACIT) measurement system: validation of version 4 of the core questionnaire","volume":"8","author":"Webster","year":"1999","journal-title":"Qual Life Res"},{"key":"key\n\t\t\t\t20180517005612_CIT0048","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1136\/gut.45.2.295","article-title":"Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease","volume":"45","author":"Younossi","year":"1999","journal-title":"Gut"},{"key":"key\n\t\t\t\t20180517005612_CIT0049","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jval.2016.02.005","article-title":"Performance and validation of Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV) in clinical trials of patients with chronic hepatitis C","volume":"19","author":"Younossi","year":"2016","journal-title":"Value Health"},{"key":"key\n\t\t\t\t20180517005612_CIT0050","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"Pharmacoeconomics"},{"key":"key\n\t\t\t\t20180517005612_CIT0051","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jhealeco.2006.09.002","article-title":"Modelling SF-6D health state preference data using a nonparametric Bayesian method","volume":"26","author":"Kharroubi","year":"2007","journal-title":"J Health Econ"},{"key":"key\n\t\t\t\t20180517005612_CIT0052","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1471-230X-10-40","article-title":"Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest)","volume":"10","author":"Poynard","year":"2010","journal-title":"BMC Gastroenterol"},{"key":"key\n\t\t\t\t20180517005612_CIT0053","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.clinbiochem.2006.01.011","article-title":"Assessment of liver fibrosis progression in patients with chronic hepatitis C and normal alanine aminotransferase values: the role of AST to the platelet ratio index","volume":"39","author":"Fabris","year":"2006","journal-title":"Clin Biochem"},{"key":"key\n\t\t\t\t20180517005612_CIT0054","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1002\/hep.27724","article-title":"Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1, -2, and -3 clinical trials","volume":"61","author":"Younossi","year":"2015","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20180517005612_CIT0055","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/hep.20659","article-title":"Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment","volume":"41","author":"Spiegel","year":"2005","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20180517005612_CIT0056","first-page":"600A","article-title":"Changes in serum neurotransmitters (NTs) and patient-reported outcomes (PROs) and neurocognitive performance (NCP) after viral eradication of hepatitis C virus (HCV)-genotype 1 (GT1)","volume":"66","author":"de Avila","year":"2017","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20180517005612_CIT0057","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/cid\/civ396","article-title":"Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response","volume":"61","author":"Simmons","year":"2015","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/66\/11\/1742\/24818030\/cix1106.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T00:19:52Z","timestamp":1570493992000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/66\/11\/1742\/4766885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,20]]},"references-count":57,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,12,20]]},"published-print":{"date-parts":[[2018,5,17]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/cix1106","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732341922.793553803","asserted-by":"object"}]},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,6,1]]},"published":{"date-parts":[[2017,12,20]]}}}